EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints

Didem Torumkuney, Summiya Nizamuddin iD, Ian Morrissey, Rendani Manenzhe, Anand Manoharan

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Didem Torumkuney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Unit, GSK, London, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Haemophilus influenzae, Streptococcus pneumoniae, Drug Resistance, Bacterial. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2018–21 from Pakistan.

Methods

MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

Results

S. pneumoniae (n = 57) and H. influenzae (n = 67) were collected from the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. The proportion of penicillin-susceptible pneumococci was 28.1% by CLSI oral/EUCAST low-dose breakpoints; 98.3%/98.2% were susceptible by EUCAST high-dose/CLSI intravenous breakpoints. Good activity (≥93.0%) was observed using CLSI or PK/PD breakpoints for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, cefpodoxime, ceftriaxone, cefuroxime, levofloxacin and moxifloxacin. Cefdinir and cefaclor were less active (75.4% and 57.9%, respectively, by CLSI and 61.4% and 19.3%, respectively, by PK/PD). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole were poorly active (5.3%–36.8%). EUCAST high-dose breakpoints indicated similar activity, although susceptibility to cefaclor (0%), cefpodoxime (70.2%) and cefuroxime (68.4%) was lower than by CLSI. Most H. influenzae isolates were β-lactamase negative (95.5%). Generally, antibiotic susceptibility was >83.6% by CLSI for all antibiotics except trimethoprim/sulfamethoxazole (13.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral), with 0% susceptible isolates versus 95.5% by CLSI and 67.2% by PK/PD, fluoroquinolones and macrolides (no EUCAST breakpoint). Macrolide susceptibility by PK/PD breakpoints was low.

Conclusions

Although antimicrobial resistance was observed, many therapeutic options remain to treat S. pneumoniae and H. influenzae from CA-RTI in Pakistan despite concerns about high levels of inappropriate antibiotic use. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHaemophilus influenzaeStreptococcus pneumoniaeDrug Resistance, BacterialHumansPakistanMicrobial Sensitivity TestsCommunity-Acquired InfectionsRespiratory Tract InfectionsAdultChildFemaleMaleMiddle AgedChild, PreschoolPneumococcal InfectionsYoung AdultAdolescentHaemophilus InfectionsInfant

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Infectious Diseases Research Unit, GSK, London, UK.
  • Department of Microbiology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
  • Antimicrobial Focus Ltd., Sawbridgeworth, UK.
  • Infectious Diseases Research Unit, GSK, Gauteng, South Africa.
  • Infectious Diseases Medical & Scientific Affairs, GSK, Mumbai, India.

ORCID-Profile: Summiya Nizamuddin

Förderung

  • GSK

Zitieren

APA

Torumkuney, D., Nizamuddin, S., Morrissey, I., Manenzhe, R., & Manoharan, A. (2025). Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf288

Vancouver

Torumkuney D, Nizamuddin S, Morrissey I, Manenzhe R, Manoharan A. Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf288

BibTeX
@article{Torumkuney2025,
  author = {Torumkuney, Didem and Nizamuddin, Summiya and Morrissey, Ian and Manenzhe, Rendani and Manoharan, Anand},
  title = {Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf288}
}
Kostenlos starten →